Granules India Limited (GRANULES) announced that it has submitted a Paragraph IV certification in connection with its ANDA for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed in the U.S. Food and Drug Administration’s (FDA) Orange Book. This move positions the company for potential first-to-file status for Ruxolitinib Extended-Release Tablets, which may grant 180 days of generic drug exclusivity under U.S. law.

Strategic Filing

The ANDA remains subject to FDA review, and this announcement should not be construed as FDA approval of the product or confirmation by the FDA of first-to-file status or exclusivity. This strategic filing reflects Granules India Limited’s focus on identifying technically and commercially attractive opportunities where its development and manufacturing capabilities can create sustainable value.

Company Outlook

Commenting on the development, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited, said: “First-to-file opportunities are an important part of our strategy to build a more differentiated and higher-value product portfolio in the U.S. This filing reflects our focus on identifying technically and commercially attractive opportunities where our development and manufacturing capabilities can create sustainable value. We look forward to progressing the product through the regulatory process.”

The company will provide further updates, as appropriate, in accordance with applicable disclosure requirements. This communication contains forward-looking statements relating to, among other things, the Company’s ANDA, potential first-to-file status, possible eligibility for 180-day exclusivity, regulatory review, and commercialization prospects. Such statements are subject to risks and uncertainties, including those relating to FDA actions, patent litigation, exclusivity determinations, competition, and other factors, and actual outcomes may differ materially from those expressed or implied herein.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Granules India Limited

Granules India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Granules holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG stands at 6.48 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock trades at 78% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises -2.7% in three months on 5.9% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Granules India Limited.

Granules India Limited (GRANULES) fell -5% to ₹829.1 on the NSE on 22 Jul 2026, backed by its Q1 FY27 results where revenue surged 22% YoY and PAT jumped 60%. The stock’s decline today can be attributed to the shift in trendline status from CONSOLIDATING UP to APPROACHING RESISTANCE, with the stock now just 1.0% away from the resistance level at ₹837. This move is also notable as the stock is currently 10% above its 50-DMA, indicating a stretched position. In the healthcare sector, specifically within drug manufacturers, Granules India’s performance reflects strong financial results but also highlights the stock’s sensitivity to technical levels and market sentiment.

Technical setup — trendlines & DMA

From a technical perspective, Granules India’s current price is navigating a critical juncture. The 6M support trendline is established at ₹762.53, which is 8.03% below today’s price, providing a solid floor. Conversely, the resistance trendline ends at ₹837.06, just 0.96% above the current price, indicating imminent resistance. The 50-DMA at ₹795.2 is below the current price, suggesting a bullish trend as the stock is trading 10.12% above this average. Additionally, the stock is significantly above the 200-DMA at ₹645.1, up 35.75%, reinforcing the bullish sentiment. Within the 52W range of ₹432.6 to ₹910.0, the current price sits in the upper third, reflecting a strong upward move but also indicating that a substantial portion of the potential gain might already be priced in.

Fundamentals & business context

On the fundamental front, Granules India’s PE of 35.8, coupled with an 11.1% profit margin and a revenue CAGR of 5.9%, suggests that the stock is trading at a premium relative to its earnings growth. This valuation might reflect market expectations of future growth, possibly driven by the company’s robust Q1 FY27 performance. The institutional holding of 21.0% indicates a moderate level of confidence from smart money, though not overwhelmingly bullish. There is no specific NSE catalyst today beyond the earnings release, which already significantly impacted the stock’s movement.

Algorithmic scorecard

The algorithmic scorecard for Granules India reflects a technically strong but fundamentally weaker profile. The stock’s technical strength is underscored by its bullish trend, with the 50-day average above the 200-day average, and its breakout status, indicating strong momentum. The stock’s low volatility, as evidenced by a beta of 0.10, also suggests a stable investment with less market risk. However, the fundamental weaknesses are notable, particularly the overvalued PEG of 7.46, which indicates the stock may be expensive relative to its growth rate. Additionally, the negligible dividend yield of 0.2% offers little income for investors, potentially limiting its appeal to income-focused investors.

Company outlook

Granules India’s management has outlined several strategic initiatives and outlooks for the coming fiscal year. The company anticipates potential U.S. product launches as approvals progress, with 9 applications awaiting clearance from the Gagillapur site. They aim to maintain a working capital to sales ratio in the 33% range despite cost escalations. For the peptide CDMO business, Granules India expects EBITDA and PAT positivity from FY ’27 onwards. In terms of capital expenditure, the company plans a broad-based approach for FY ’27, including a new API facility, IT investments, and a distribution center in the U.S.A., with a planned capex in the range of INR 600-odd crores, including INR 200 crores plus for the distribution center. Additionally, there are investments planned for a brownfield manufacturing facility for peptide intermediates in India, followed by a peptide API capacity.

Get all details on GRANULES — P&L, peers, shareholding and more on TradeAlone.

Granules India Limited (GRANULES) today announced its financial results for the quarter ended June 30, 2026. The company reported a revenue from operations of INR 14,768 Mn, marking a 22% year-on-year growth. The EBITDA stood at INR 3,389 Mn, up 37% YoY, while the PBT before exceptional item was INR 2,404 Mn, up 41% YoY. The PAT reached INR 1,800 Mn, showing a 60% increase compared to the same quarter last year.

Financial Summary

The financial summary for Q1 FY27 highlights a robust performance across key metrics. The revenue from operations grew by 22% YoY, EBITDA increased by 37% YoY, PBT before exceptional items rose by 41% YoY, and PAT surged by 60% YoY. Despite a 4% QoQ decline in EBITDA, the company’s strong performance in PAT reflects its strategic focus on operational excellence and growth.

Market and Operational Insights

The company’s revenue share from North America decreased slightly to 72% in Q1 FY27 from 77% in Q1 FY26, while the share from Europe increased to 16% from 13%. Finished dosages, Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides CDMO contributed 74%, 13%, 9%, and 4% of revenue respectively. The Return on Capital Employed (ROCE) improved to 18.0% in Q1 FY27 from 17.6% in FY26. Net debt reduced to INR 1,012 Mn, a significant decrease from INR 9,479 Mn in Q1 FY26.

Forward-Looking Statement

Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited, said, “Q1 FY27 marks an important step forward for Granules India as the foundations strengthened during FY26 begin to translate into greater execution confidence, strategic clarity, and business resilience. Our focus remains firmly on regulatory and quality excellence, portfolio transformation toward complex and differentiated products, geographic and customer diversification, and scaling new growth engines. While external cost pressures and supply chain volatility require continuous management for the next couple of quarters, we are continuing to invest in R&D largely towards Complex Gx, digitalization, operational excellence, sustainability, and talent to support long-term value creation. With a stronger organization, a more balanced portfolio, and clear strategic priorities, we remain confident in Granules’ ability to deliver sustainable growth for all stakeholders.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Granules India Limited

Granules India Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Granules gains 31.2% over three months and trades near its 52-week highs. The PEG stands at 7.46 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock trades at 93% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 31.2% in three months. Yet revenue grows at only 5.9% and the PEG stands at 7.46. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Granules India Limited.